大流行前慢性肾脏病与急性及急性后COVID-19的关联:C4R研究
该前瞻性队列纳入9项美国人群研究的26,039名成人,评估大流行前CKD分期与COVID-19住院或死亡、长新冠指数阳性及疫苗接种后抗S1 IgG水平的关系。结果显示CKD分期越高,重症COVID-19风险越高、抗S1 IgG水平越低;仅极高分期CKD感染者的长新冠指数阳性率升高。
要点
- CKD分期越高,重症COVID-19风险越高,极高分期HR达2.72。
- CKD分期越高,疫苗接种后抗S1 IgG水平越低,极高分期降低48.9%。
- 仅极高分期CKD感染者的长新冠指数阳性率升高,OR为2.20。
核心结论
- 较高CKD分期与重症COVID-19风险增加和抗S1抗体应答降低相关。
- 除极高分期CKD个体外,CKD分期与长新冠指数阳性无一致关联。
研究设计与样本
- 前瞻性队列研究,纳入9项自1971年起建立的美国人群研究中的成人。
- 共26,039名参与者,均有大流行前CKD测量和COVID-19结局随访。
主要发现
- 中位随访550天(IQR 314-636),734人发生重症COVID-19。
- 感染患者中12.1%(669/5,527)为长新冠指数阳性;3.1%(82/2,679)抗S1 IgG无反应。
- 中度CKD重症COVID-19的HR为1.27(95%CI 1.03-1.56),高度为2.33(1.77-3.06),极高为2.72(1.88-3.92)。
- 抗S1 IgG水平变化:中度CKD -12.00%(95%CI -21.14%至-1.78%),高度-27.03%(-40.00%至-11.25%),极高-48.9%(-61.60%至-32.01%)。
- 仅极高分期CKD感染者的长新冠指数阳性率升高,OR为2.20(95%CI 1.16-4.18)。
临床怎么用
- 对晚期CKD患者应加强COVID-19预防措施和疫苗应答监测。
局限性
- 部分结局为自我报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Kidney failure is associated with severe COVID-19, but data on early stage chronic kidney disease (CKD) and its relationship to acute and post-acute COVID-19 as well as postvaccination antibody responses are limited. We evaluated pre-pandemic CKD stage in relation to these outcomes. STUDY DESIGN: Prospective cohort. SETTING & PARTICIPANTS: Adults in 9 US population-based studies established since 1971, with pre-pandemic CKD measurements and follow-up for COVID-19 outcomes. EXPOSURE: CKD stages (low CKD stage [reference], moderate CKD stage, high CKD stage, and very high CKD stage) defined by creatinine-based eGFR and urinary albumin-creatinine ratio. OUTCOME: (1) COVID-19 hospitalization or death (self-report/medical records, 2020-2023); (2) RECOVER Long COVID Research Index score ≥11 (LCRI-positivity by questionnaires, 2023-2024); (3) post-vaccination anti-spike 1 (S1) IgG levels (dried blood spots, 2021‒2022). ANALYTICAL APPROACH: Cause-specific hazards for severe COVID-19, logistic regression for LCRI positivity, and generalized additive models for anti-S1 IgG. RESULTS: Among 26,039 participants, CKD stage was low in 81.7%, moderate in 13.0%, high in 3.6%, and very high in 1.7%. Over a median 550-day follow-up period (IQR, 314-636), 734 had severe COVID-19; 12.1% of infected patients (669 of 5,527) were classified as LCRI positive; and 3.1% (82 of 2,679) were anti-S1 IgG antibody nonreactive. A more severe CKD stage was associated with a greater risk for severe COVID-19: the HR for moderate stage CKD was 1.27 (95% CI, 1.03-1.56), for high stage CKD, 2.33 (1.77-3.06), and for very high stage CKD, 2.72 (1.88-3.92). Higher CKD stages were associated with lower anti-S1 IgG levels: -12.00% (95% CI, -21.14% to -1.78%) for moderate stage CKD, -27.03% (95% CI, -40.00% to -11.25%) for high stage CKD, and -48.9% (95% CI, -61.60% to -32.01%) for very high stage CKD. A higher prevalence of LCRI positivity was observed only among infected individuals with very high stage CKD (odds ratio, 2.20 [95% CI, 1.16-4.18]). LIMITATIONS: Some outcomes were self-reported. CONCLUSIONS: Higher CKD stages were associated with a greater risk for severe COVID-19 and a lower anti-S1 antibody response. No consistent association was observed between CKD stage and LCRI positivity except in individuals with very high stage CKD. PLAIN-LANGUAGE SUMMARY: Chronic kidney disease (CKD) affects approximately 1 in 7 US adults, yet its impact on COVID-19 outcomes, particularly in early stage CKD, remains incompletely understood. We analyzed pre-pandemic CKD stage data from 9 population-based US cohorts to assess their associations with the risk of severe COVID-19, symptom-defined long COVID, and postvaccination anti-spike 1 IgG levels. More advanced stages of CKD had a stronger relationship with severe COVID-19 and a lower anti-S1 antibody response. No consistent association was observed with symptom-defined long COVID, although its prevalence was higher among individuals with very high stage CKD. These findings suggest an altered vaccine-induced immunity and increased susceptibility to both acute and post-acute COVID-19 outcomes among persons with advanced CKD. Adults with advanced CKD may benefit from targeted preventive measures.
引用
- Choi Y, Jacobs DR, Kramer HJ, et al. Associations of Pre-Pandemic CKD With Acute and Post-Acute COVID-19: The C4R Study. Am J Kidney Dis. 2026. PMID: 42362101. doi:10.1053/j.ajkd.2026.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。